Advertisement

Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy

  • Yanshuo Cao
  • Qing Chang
  • Wenjiang Zhang
  • Olga Ornatsky
  • David Hedley
  • Eric X. ChenEmail author
Original Article

Abstract

Background

Oxaliplatin is widely used in the treatment of gastrointestinal malignancies. One of the most common and dose-limiting side effects of oxaliplatin is the chronic peripheral sensory neuropathy. The mechanism of this neurotoxicity is poorly understood and there are no effective preventive or treatment strategies, other than oxaliplatin dose interruption or reduction.

Methods

Colorectal cancer patients who completed FOLFOX at least 6 months prior to enrollment were eligible. EORTC QLQ-CIPN20 questionnaire was used for assessing self-reported neuropathic symptom. Blood samples and skin biopsies were obtained and analyzed for platinum.

Results

Twelve patients were enrolled. The mean cumulative dose of oxaliplatin was 818 ± 54 mg/m2, and the median time from last dose of oxaliplatin was 38.7 months (range: 7.2–65.6 months). The QLQ-CIPN20 sensory score was 18 or less in 10 patients and 19 and 25, respectively, in 2 patients. Platinum was detectable in plasma from 4/12 patients up to 63.3 months after the completion of FOLFOX. In all six patients with skin biopsies, platinum was present in the skin with imaging mass cytometry.

Conclusions

QLQ-CIPN20 scores and plasma platinum concentrations were not related to cumulative doses of oxaliplatin or interval from the last dose of oxaliplatin. Platinum was readily detectable in skin biopsies more than 60 months post-completion of FOLFOX. This is the first demonstration of platinum deposition in skin post-oxaliplatin treatment and it provides a possible mechanism for oxaliplatin-induced peripheral sensory neuropathy and its persistence.

Keywords

Colorectal cancer Platinum Peripheral sensory neuropathy Oxaliplatin Image mass cytometry 

Notes

Acknowledgements

We thank Jing Xu for valuable technical assistance.

Funding

Funding for this study was provided by Princess Margaret Cancer Center Foundation.

Compliance with ethical standards

Conflict of interest

Qing Chang and Olga Ornatsky are employees of Fluidigm Canada Inc. Olga Ornatsky is one of the co-founders of DVS Sciences Inc. (now part of Fluidigm) that invented, developed and manufactures mass cytometry technologies, including the Helios CyTOF system, the Imaging Mass Cytometer and metal-conjugated reagents. No other authors declared any potential conflicts of interest.

References

  1. 1.
    Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351CrossRefGoogle Scholar
  2. 2.
    de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947CrossRefGoogle Scholar
  3. 3.
    Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019CrossRefGoogle Scholar
  4. 4.
    Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825CrossRefGoogle Scholar
  5. 5.
    Conroy T, Hammel P, Hebbar M et al (2018) FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395–2406CrossRefGoogle Scholar
  6. 6.
    Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46CrossRefGoogle Scholar
  7. 7.
    Bang YJ, Kim YW, Yang HK et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315–321CrossRefGoogle Scholar
  8. 8.
    Andre T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116CrossRefGoogle Scholar
  9. 9.
    Pasetto LM, D’Andrea MR, Rossi E et al (2006) Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 59:159–168CrossRefGoogle Scholar
  10. 10.
    Loprinzi CL, Qin R, Dakhil SR et al (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997–1005CrossRefGoogle Scholar
  11. 11.
    de Andrade DC, Jacobsen Teixeira M, Galhardoni R et al (2017) Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: a randomized double-blind trial. Oncologist 22:1154-e105CrossRefGoogle Scholar
  12. 12.
    Tournigand C, Cervantes A, Figer A et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol 24:394–400CrossRefGoogle Scholar
  13. 13.
    Adams RA, Meade AM, Seymour MT et al (2011) Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 12:642–653CrossRefGoogle Scholar
  14. 14.
    Hochster HS, Grothey A, Hart L et al (2014) Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol 25:1172–1178CrossRefGoogle Scholar
  15. 15.
    Grothey A, Sobrero AF, Shields AF et al (2018) Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 378:1177–1188CrossRefGoogle Scholar
  16. 16.
    Alberts SR, Sargent DJ, Nair S et al (2012) Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307:1383–1393CrossRefGoogle Scholar
  17. 17.
    Lavoie Smith EM, Barton DL, Qin R et al (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22:2787–2799CrossRefGoogle Scholar
  18. 18.
    Levitt J, Bernardo S, Whang T (2013) Videos in clinical medicine. How to perform a punch biopsy of the skin. N Engl J Med 369:e13CrossRefGoogle Scholar
  19. 19.
    Misery L, Bodere C, Genestet S et al (2014) Small-fibre neuropathies and skin: news and perspectives for dermatologists. Eur J Dermatol 24:147–153Google Scholar
  20. 20.
    Cao Y, Chang Q, Cabanero M et al (2018) Tumor platinum concentrations and pathological responses following cisplatin-containing chemotherapy in gastric cancer patients. J Gastrointest Cancer.  https://doi.org/10.1007/s12029-018-0153-9 Google Scholar
  21. 21.
    Chang Q, Ornatsky OI, Siddiqui I et al (2017) Imaging mass cytometry. Cytometry A 91:160–169CrossRefGoogle Scholar
  22. 22.
    Lehky TJ, Leonard GD, Wilson RH et al (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29:387–392CrossRefGoogle Scholar
  23. 23.
    Krishnan AV, Goldstein D, Friedlander M et al (2006) Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res 12:4481–4484CrossRefGoogle Scholar
  24. 24.
    Jerremalm E, Wallin I, Ehrsson H (2009) New insights into the biotransformation and pharmacokinetics of oxaliplatin. J Pharm Sci 98:3879–3885CrossRefGoogle Scholar
  25. 25.
    Gamelin E, Bouil AL, Boisdron-Celle M et al (1997) Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res 3:891–899Google Scholar
  26. 26.
    Sprauten M, Darrah TH, Peterson DR et al (2012) Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. J Clin Oncol 30:300–307CrossRefGoogle Scholar
  27. 27.
    Breglio AM, Rusheen AE, Shide ED et al (2017) Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun 8:1654CrossRefGoogle Scholar
  28. 28.
    Gorodetsky R, Mou X, Vexler A et al (1993) Noninvasive follow-up of platinum pharmacokinetics in the skin of patients on cisplatin chemotherapy. Cancer 72:446–454CrossRefGoogle Scholar
  29. 29.
    Ta LE, Espeset L, Podratz J et al (2006) Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27:992–1002CrossRefGoogle Scholar
  30. 30.
    Jamieson SM, Liu J, Connor B et al (2005) Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 56:391–399CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Yanshuo Cao
    • 1
    • 2
  • Qing Chang
    • 3
  • Wenjiang Zhang
    • 1
  • Olga Ornatsky
    • 3
  • David Hedley
    • 1
    • 2
  • Eric X. Chen
    • 1
    • 2
    Email author
  1. 1.Department of Medical Oncology and Hematology, Princess Margaret Cancer CentreUniversity Health NetworkTorontoCanada
  2. 2.Faculty of MedicineUniversity of TorontoTorontoCanada
  3. 3.Fluidigm Canada Inc.MarkhamCanada

Personalised recommendations